An overview of endpoints for cystic fibrosis clinical trials: One size does not fit all

Proceedings of the American Thoracic Society

Volumn 4, Issue 4, 2007, Pages 299-301

  Rosenfeld, Margaret ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Cystic fibrosis; Endpoints; Imaging

Indexed keywords

ANTIBIOTIC AGENT; COLISTIN; MACROLIDE; TOBRAMYCIN;

BACTERIAL INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CYSTIC FIBROSIS; DISEASE EXACERBATION; GENE THERAPY; HUMAN; INFECTION PREVENTION; LUNG DISEASE; LUNG FUNCTION; MEDICAL RESEARCH; OUTCOME ASSESSMENT; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; SPIROMETRY; THORAX RADIOGRAPHY;

CLINICAL TRIALS; CYSTIC FIBROSIS; HUMANS;

EID: 34548288533     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200611-178HT     Document Type: Conference Paper

References (4)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
2. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440.
3. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28:321-328.
4. Quittner AL, Sweeny S, Watrous M, Munzenberger P, Bearss K, Gibson Nitza A, Fisher LA, Henry B. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol 2000;25:403-414.